



Demographic and Clinical Profiles of Hemodialysis Patients Exhibiting Low PTH Levels and Adynamic Bone Disease

Zahra Kamiab^{1,2}, Gholamreza Bazmandegan^{3,4}, Fatemeh Jalali Khalilabadi^{5,6}, Mohammad Khalil Salehi⁷, Mahdieh Jamshidi^{6,8*}

¹Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

²Department of Community Medicine, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

³Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

⁴Department of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

⁵Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

⁶Department of Internal Medicine, Ali-Ibn Abi-Talib Hospital, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

⁷Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

⁸Clinical Research Development Unit, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

*Corresponding Author: Mahdieh Jamshidi, Email: jamshidi.mn@gmail.com

Abstract

Introduction: Adynamic bone disease (ABD) is a condition that arises as a complication of chronic kidney disease, and biomarkers offer valuable insights into bone health in these patients. Parathyroid hormone (PTH) levels are commonly used as an indicator of bone turnover, with low PTH levels (<100 pg/mL) associated with ABD. This study described the demographic and clinical characteristics of individuals experiencing low PTH levels and evaluated the potential association between low PTH and ABD.

Methods: A cross-sectional study was conducted on 64 patients undergoing hemodialysis. The patients were divided into two groups: those with PTH levels < 100 pg/mL (n = 10) and those with PTH ≥ 100 pg/mL (n = 54). Demographic, clinical, and laboratory data, including vitamin D levels and bone biomarkers, were analyzed.

Results: Patients with reduced PTH levels demonstrated notably elevated vitamin D concentrations ($P=0.001$) alongside decreased serum albumin levels ($P=0.018$). No significant differences were found in other parameters, including calcium and alkaline phosphatase levels.

Conclusion: Although PTH levels are commonly used to predict bone turnover, this study acknowledges the limitation of using PTH without bone biopsy for diagnosing ABD. Additional research is required to investigate the role of vitamin D in managing ABD.

Keywords: Renal dialysis, Parathyroid hormone, Bone disease, Renal insufficiency, Chronic, Vitamin D

Citation: Kamiab Z, Bazmandegan G, Jalali Khalilabadi F, Salehi MK, Jamshidi M. Demographic and clinical profiles of hemodialysis patients exhibiting low PTH levels and adynamic bone disease. Journal of Kerman University of Medical Sciences 2026;33:4091. doi:10.34172/jkmu.4091

Received: November 15, 2025, **Accepted:** December 29, 2025, **ePublished:** April 4, 2026

Introduction

Chronic Kidney Disease (CKD) develops when the kidneys sustain damage and can no longer filter blood efficiently for a period of at least three months. As a result, excess fluids and waste accumulate in the body, potentially leading to various health complications, including heart disease, stroke, infections, and bone disorders (1, 2). In 2019, CKD ranked 15th in global mortality, resulting in 1.2 million deaths and 35.8 million disability-adjusted life years (DALYs) (3). As CKD progresses, mortality rates rise; about 50% of stage 5 CKD patients do not survive beyond five years, while ESRD patients face an even greater risk, with approximately 20% not surviving the first year of

dialysis initiation (2, 4). In the U.S., ESRD remains stable at approximately 120,000 new cases annually, primarily due to diabetes and hypertension, which account for around 70% of cases (5). Chronic kidney disease (CKD) and its advanced stage, end-stage renal disease (ESRD), present significant challenges to Iran's healthcare system (6, 7). Iran similarly experiences a rise in ESRD cases, with approximately 22,000 new cases each year, driven by these factors (8). In this country, the prevalence of CKD is estimated to be 11%-15%, and recent studies have reported a rate of 23.7% in the northeast (6, 8, 9). A meta-analysis reveals that the prevalence of CKD in Iran is higher than that in other developing nations and comparable to developed countries



(10).

As kidney function declines, mineral balance becomes disrupted, influencing calcium, phosphorus, and parathyroid hormone (PTH) concentrations, which in turn impacts bone health (11, 12). This can lead to two primary bone disorders: increased bone turnover as a result of secondary hyperparathyroidism and decreased turnover associated with adynamic bone disease (ABD) (13). Secondary hyperparathyroidism is characterized by excessive PTH secretion due to hypocalcemia, often linked to CKD or conditions that impair vitamin D synthesis or action (14). In contrast, ABD is marked by reduced bone turnover resulting from suppressed activity of bone-forming cells (osteoblasts) and bone-resorbing cells (osteoclasts), which plays a crucial role in bone health. An imbalance in their function can result in bone loss and elevate the risk of fractures (15). Factors contributing to ABD include excessive suppression of PTH production, systemic inflammation, and altered bone management strategies in kidney disease patients (13, 16). ABD prevalence is notable within CKD, affecting 18% of CKD stages 3-5 patients. Diagnosing ABD typically needs a bone biopsy, not commonly performed in regular clinical practice, potentially leading to an underestimation of its prevalence (17). Symptoms of ABD, such as bone pain, muscle weakness, and mobility issues, can overlap with those of other bone disorders in CKD patients (18).

Research indicates a U-shaped relationship between low and extremely high levels of PTH and the associated risk of sudden death (14). Low PTH levels (below 50 pg/mL) are notably linked to reduced survival rates in patients undergoing hemodialysis (19, 20). Diagnosis of ABD relies on laboratory tests that measure indicators like parathyroid hormone and alkaline phosphatase, and tartrate-resistant acid phosphatase, complemented by imaging studies (13). This study aimed to investigate biomarker levels in hemodialysis patients, comparing those with ABD to those without it.

Methods

Study Design and Sample

This descriptive-analytical study employed a census sampling method to select 64 hemodialysis patients from Ali-Ibn Abi-Talib Hospital in 2021-2022.

Informed consent and ethical approval

Informed consent was obtained from all patients for the publication of their anonymized data in this article. This study received ethical approval from the Ethics Committee of Rafsanjan University of Medical Sciences (Ethical code: IR.RUMS.REC.1401.123).

Data collection

Data were collected using a researcher-made checklist to gather demographic information, including age, sex, patient weight, underlying diseases, dialysis duration, and weekly dialysis hours, all obtained from the patients' files in the dialysis department. Additionally, we recorded data on

calcium, phosphorus, vitamin D, C-reactive protein (CRP), albumin, total alkaline phosphatase, creatinine (monitored monthly), and parathyroid hormone (PTH) levels (checked every three months).

Inclusion and Exclusion Criteria

Inclusion criteria encompassed all hemodialysis patients at Ali-Ibn Abi-Talib Hospital with a dialysis history exceeding three months. Exclusion criteria included patients receiving supraphysiological or therapeutic doses of calcium and vitamin D, those with incomplete medical records, and patients with acute infections, connective tissue diseases, malignancies, chronic liver diseases, thyroid disorders, recent heart attacks, trauma within the last six months, postmenopausal women, and those unwilling to participate or who had deceased (6, 13, 15).

Measures

We considered symptoms or complications such as osteoporosis, kidney stones, abdominal pain, constipation, fatigue, depression, cognitive impairment, imaging studies (ultrasound, CT, MRI), and bone mineral density (BMD) measurements (21, 22). Adynamic bone disease (ABD) was defined as a type of renal osteodystrophy associated with reduced bone turnover, reduced bone formation, and increased bone mineralization. Diagnostic criteria for ABD included a mineralized bone volume of less than 10% of the biopsy area, minimal or absent osteoblasts or osteoclasts, normal to low serum alkaline phosphatase (ALP) levels, serum PTH levels below 150 pg/mL, normal to low bone-specific alkaline phosphatase levels, and normal to low urinary deoxypyridinoline levels (21, 22).

Statistical Analysis

Statistical analyses were conducted using SPSS software version 24 (IBM SPSS Inc., Chicago, IL, USA). Quantitative data are expressed as mean $\pm$ standard deviation along with the range of values, whereas qualitative data are presented as frequencies (percentages). An independent two-sample t-test was performed to evaluate the differences in mean values of quantitative variables between the two groups. Pearson's correlation coefficients were calculated to assess the relationships between disease duration, hemodialysis duration, and laboratory parameters.

Results

The study comprised 64 participants, with 32 men (50%) and a mean age of 62.97 ± 14.93 years. The mean duration of disease and the mean duration of dialysis per week were 3.45 ± 2.83 years and 8.65 ± 1.85 hours, respectively (Table 1).

The prevalence of ABD among the participants was 15.6% (10 individuals). Independent samples t-tests were conducted to examine the distribution of variables between patients with and without ABD, as detailed in Table 2.

Among men, the prevalence of ABD was 18.8%, while it was 12.5% in women; the difference was not statistically significant ($P = 0.491$). Notably, individuals without ABD

exhibited significantly higher mean levels of serum albumin and parathyroid hormone (PTH) compared to those with ABD ($P=0.018$ and $P<0.001$, respectively). Furthermore, participants with ABD had significantly higher mean vitamin D levels than those without ABD ($P<0.001$).

A moderately strong positive correlation was observed between disease duration and serum creatinine levels ($P=0.001$). Furthermore, a weak positive and significant correlation was observed between dialysis duration and serum alkaline phosphatase levels ($P=0.017$). A notable

moderate positive correlation was identified between the length of hemodialysis treatment and PTH levels (Table 3).

Discussion

ABD is a complication associated with chronic kidney disease, with biomarkers providing crucial information about bone health in affected patients (22). In the present study, 15.6% of the participants were diagnosed with ABD among hemodialysis patients. A parallel investigation conducted by Malluche et al. examined ABD prevalence among a group of U.S. hemodialysis patients, revealing an overall prevalence of 28.8%, with higher rates in older patients and those with longer dialysis durations (23). Similar studies reported ABD prevalence rates of 29.9% in African American hemodialysis patients (24). Another study by Tentori et al. investigated ABD prevalence in a large cohort of hemodialysis patients across Europe and Japan, uncovering significant variations ranging from 6.5% to 51.1% among countries (25).

In the present study, no significant gender-based difference in ABD was observed. In terms of gender, a study conducted by Uhlig et al. reported a higher prevalence of ABD in female hemodialysis patients compared to males, contrasting with our findings where a smaller percentage of female patients had ABD (13). It is important to recognize that variations in sample size, participant characteristics, diagnostic criteria, and measurement methods for bone turnover markers can influence study outcomes and lead to discrepancies between the findings.

Table 1. Demographic and Clinical Characteristics of Hemodialysis Patients (n=64)

Variables	Mean $\pm$ SD	Min-Max
Age (Years)	62.97 $\pm$ 14.93	25-87
Weight (Kg)	63.89 $\pm$ 11.84	37-89
Duration of disease (years)	3.45 $\pm$ 2.83	0.33-13
Serum Albumin (g/dL)	3.71 $\pm$ 0.41	2.4-4.4
Serum Creatinine (mg/dL)	7.29 $\pm$ 2.28	2.61-9.6
Serum Vitamin D (ng/mL)	37.22 $\pm$ 70.06	2-558
Serum Alkaline Phosphatase (IU/L)	313.80 $\pm$ 184.31	133-1216
Serum Calcium (mg/dL)	8.04 $\pm$ 0.93	5.7-9.8
Serum Phosphorus (mg/dL)	6.05 $\pm$ 1.66	2.9-9.6
Serum C-reactive Protein (mg/L)	8.83 $\pm$ 18.77	1-110
Serum parathyroid hormone levels (pg/mL)	596.84 $\pm$ 422.90	53-1494
Duration of Dialysis per Week (hours)	8.65 $\pm$ 1.85	2.50-10.50

The data were expressed as mean $\pm$ standard deviation and minimum – maximum.

Table 2. Comparison of Variable Distribution between Groups with and without Adynamic bone disease (n=64)

Variables	Adynamic bone disease (n=10)	Non-adynamic bone disease (n=54)	P-value
Age (Years)	68.30 $\pm$ 14.76	61.98 $\pm$ 14.88	0.222*
Duration of disease (Years)	2.60 $\pm$ 2.20	2.83 $\pm$ 3.68	0.129*
Duration of hemodialysis (Weeks)	7.65 $\pm$ 2.59	8.84 $\pm$ 1.64	0.190*
Weight (Kg)	60.20 $\pm$ 7.03	64.57 $\pm$ 12.45	0.287*
Serum Albumin (g/dL)	3.43 $\pm$ 0.49	3.76 $\pm$ 0.37	0.018*
Serum Creatinine (mg/dL)	6.67 $\pm$ 2.87	7.38 $\pm$ 2.17	0.429*
Serum Vitamin D (ng/mL)	72.69 $\pm$ 170.84	30.65 $\pm$ 24.43	0.001*
Serum Alkaline Phosphatase (IU/L)	255.20 $\pm$ 186.23	324.64 $\pm$ 183.63	0.277*
Serum Calcium (mg/dL)	8.35 $\pm$ 0.72	7.98 $\pm$ 0.96	0.254*
Serum Phosphorus (mg/dL)	5.43 $\pm$ 1.09	6.16 $\pm$ 1.73	0.202*
Serum C-reactive Protein (mg/L)	4.20 $\pm$ 5.69	9.68 $\pm$ 20.21	0.400*
Serum parathyroid hormone levels (pg/mL)	97.00 $\pm$ 34.60	689.40 $\pm$ 395.62	0.001*

The data were expressed as mean $\pm$ standard deviation.

* P-value obtained from two-sample independent t-test due to normal distribution. $P<0.05$ was considered statistically significant.

Table 3. Correlation between duration of disease and dialysis and laboratory parameters

		Albumin	Creatinine	Vit D	Alkaline phosphatase	Calcium	phosphorus	C-reactive protein	Parathyroid hormone levels
Duration of disease	Pearson Correlation	0.014	0.439*	0.009	0.298*	-0.217	0.244	0.022	0.299
	P-value	0.915	0.001	0.942	0.017	0.085	0.052	0.862	0.069
Duration of hemodialysis	Pearson Correlation	0.199	0.176	-0.109	0.299	-0.182	0.049	-0.043	0.328**
	P-value	0.115	0.165	0.389	0.069	0.150	0.700	0.737	0.008

* P-value obtained from correlation.

$P<0.05$ was considered statistically significant.

The findings of this study indicate a weak positive relationship between disease duration and albumin and creatinine levels. Serum albumin is recognized as an important indicator of mortality in individuals with chronic kidney disease (CKD). Previous studies have also investigated its role in ESRD development (26, 27). In a retrospective cohort analysis in the UK in 2011 that examined 1,800 individuals, serum albumin levels were identified as a crucial component in a multifactorial risk model for mortality in ESRD patients (26). In contrast, a study on Chinese hemodialysis patients in 2016 showed a negative relationship between hemodialysis duration and serum albumin levels, suggesting that longer hemodialysis was associated with lower albumin levels (28). In Japanese hemodialysis patients, reduced levels of serum albumin were linked to ABD, indicating that reduced albumin levels may heighten the risk of this condition (29). Another study in Japan also reported significantly lower serum albumin levels in ABD patients, and low albumin levels have been identified as an independent risk factor for the disease (30). These findings support the notion that low serum albumin levels could potentially increase the risk of ABD in individuals undergoing hemodialysis. It is essential to recognize that the strength and direction of these associations may be influenced by specific patient characteristics and uncontrolled variables in our study.

This study identified a slight inverse relationship between the duration of the disease and vitamin D levels, in line with the findings of Yashiro et al. regarding lower vitamin D levels in longer hemodialysis patients (31). Interestingly, our patient group displayed higher average vitamin D levels than the disease-free group, contrasting with studies from the United States and India associating low vitamin D levels with a higher risk of ABD in patients undergoing hemodialysis (32). Further investigation is needed to validate these discrepancies, considering potential differences in vitamin D supplementation and other factors.

In our study, a moderately significant positive correlation was identified between the duration of hemodialysis and PTH levels, indicating that as the disease progresses, parathyroid hormone levels tend to rise. This finding was consistent with the findings of prior research, including studies in Japanese and European cohorts (25, 33). Conversely, the correlation between disease duration and alkaline phosphatase, calcium, and CRP was weak and statistically insignificant, consistent with similar investigations (34, 35). Notably, in the group with ABD, PTH levels were noticeably lower compared to the group without the condition, contrasting with the findings of the studies associating elevated PTH levels with ABD risk, suggesting potential variations in PTH management or other influencing factors that warrant further investigation into the relationship between PTH levels and ABD (36, 37). However, it is important to highlight that increased normalized alkaline phosphatase levels have been linked to hemodialysis patients face an increased risk of hospitalization and mortality, regardless of calcium and

phosphorus levels and parathyroid hormone levels, which is inconsistent with our findings (35).

Comparing variables between groups with and without ABD showed no significant difference in age, disease duration, or average weight. While some studies have linked older age and longer dialysis duration to a higher risk of ABD (36, 38), the relatively small proportion of ABD cases (15.6%) in our study suggests a need for further investigation into clinical factors. Additionally, average levels of creatinine, alkaline phosphatase, calcium, phosphorus, and C-reactive protein did not significantly differ between the patient groups, which is consistent with the findings indicating these biomarkers may not strongly predict dynamic bone disease in hemodialysis patients (39, 40).

This research has some limitations. First, the reliance on biomarker levels alone for assessing ABD may not capture the full spectrum of clinical indicators related to the condition. Second, the limited sample size and targeted demographics due to census sampling limit the generalizability of the findings to broader hemodialysis populations. Additionally, the cross-sectional design limits the ability to draw causal conclusions about the relationships between biomarkers and ABD. Variations in treatment protocols among participating hospitals may also introduce confounding variables. Future studies should address these limitations for a more comprehensive understanding of ABD in hemodialysis patients.

Conclusion

ABD is a significant clinical concern in CKD, primarily arising from decreased osteoanabolic stimulation. This study identified a positive correlation between disease duration and parathyroid hormone (PTH) and creatinine levels. Notably, patients with ABD exhibited higher vitamin D levels but lower albumin and PTH levels compared to those without ABD. Therefore, the current therapeutic strategy for dialysis patients with CKD and ABD should emphasize optimizing vitamin D management to restore PTH activity and improve overall bone health.

Acknowledgements

The authors of this thesis express their gratitude to the Clinical Research Development Unit of Rafsanjan Ali-Ibn Abi-Talib Hospital for their invaluable cooperation and support in conducting this project.

Authors' Contribution

Conceptualization: Mahdieh Jamshidi, Zahra Kamiab, Gholamreza Bazmandegan.

Data curation: Mahdieh Jamshidi, Fatemeh Jalali Khalilabad, Mohammad Khalil Salehi.

Formal analysis: Zahra Kamiab.

Funding acquisition: Mahdieh Jamshidi.

Investigation: Mahdieh Jamshidi, Zahra Kamiab, Gholamreza Bazmandegan.

Methodology: Mahdieh Jamshidi, Zahra Kamiab, Gholamreza Bazmandegan.

Project administration: Mahdieh Jamshidi.

Resources: Mahdieh Jamshidi, Fatemeh Jalali Khalilabadi, Mohammad Khalil Salehi.

Software: Zahra Kamiab.

Supervision: Gholamreza Bazmandegan.

Validation: Mahdieh Jamshidi, Zahra Kamiab, Gholamreza Bazmandegan.

Visualization: Mahdieh Jamshidi, Fatemeh Jalali Khalilabadi, Gholamreza Bazmandegan.

Writing—original draft: Mahdieh Jamshidi, Zahra Kamiab, Gholamreza Bazmandegan.

Competing Interests

The authors declare that they have no conflicts of interest.

Data Availability Statement

Data used to support the findings of this study are included within the article.

Ethical Approval

This study was approved by the Ethics Committee of Rafsanjan University of Medical Sciences in Rafsanjan, Iran (Ethical code: IR.RUMS.REC.1401.123).

Funding

This research was funded by Rafsanjan university of medical sciences.

References

- Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine. McGraw Hill; 2022.
- Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. *Lancet* 2013;382(9888):260-72. doi:10.1016/S0140-6736(13)60687-x
- Stats F. National Chronic Kidney Disease Fact Sheet, 2017. US Department of Health and Human Services, Centers for Disease Control and Prevention; 2017.
- Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen X, Gipson D, et al. US renal data system 2019 annual data report: epidemiology of kidney disease in the United States. *Am J Kidney Dis* 2020;75(1 Suppl 1):A6-7. doi:10.1053/j.ajkd.2019.09.003
- Saran R, Robinson B, Abbott KC, Agodoa LY, Albertus P, Ayanian J, et al. US renal data system 2016 annual data report: epidemiology of kidney disease in the United States. *Am J Kidney Dis* 2017;69(3 Suppl 1):A7-8. doi:10.1053/j.ajkd.2016.12.004
- Seyedzadeh A, Tohidi MR, Golmohamadi S, Omrani HR, Seyedzadeh MS, Amiri S, et al. Prevalence of renal osteodystrophy and its related factors among end-stage renal disease patients undergoing hemodialysis: report from Imam Reza Referral Hospital of Medical University of Kermanshah, Iran. *Oman Med J* 2022;37(1):e335. doi:10.5001/omj.2021.120
- Raeisi Shahraki H, Kalantari S, Nafar M. Classification of chronic kidney disease patients via K-important neighbors in high dimensional metabolomics dataset. *J Kerman Univ Med Sci* 2019;26(3):207-13. doi:10.22062/jkmu.2019.89501
- Najafi I, Shakeri R, Islami F, Malekzadeh F, Salahi R, Yapan-Gharavi M, et al. Prevalence of chronic kidney disease and its associated risk factors: the first report from Iran using both microalbuminuria and urine sediment. *Arch Iran Med* 2012;15(2):70-5.
- Ghajarieh Sepanlou S, Barahimi H, Najafi I, Kamangar F, Poustchi H, Shakeri R, et al. Prevalence and determinants of chronic kidney disease in northeast of Iran: results of the Golestan cohort study. *PLoS One* 2017;12(5):e0176540. doi:10.1371/journal.pone.0176540
- Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. *PLoS One* 2016;11(7):e0158765. doi:10.1371/journal.pone.0158765
- Pazianas M, Miller PD. Current understanding of mineral and bone disorders of chronic kidney disease and the scientific grounds on the use of exogenous parathyroid hormone in its management. *J Bone Metab* 2020;27(1):1-13. doi:10.11005/jbm.2020.27.1.1
- Yagmaei B, Sandgol H, Abasnejhad M. Sunlight effect on Ca and P serum concentration and factors influencing on regulation of two Ions. *J Kerman Univ Med Sci* 1994;1(3):133-6. [Persian].
- Uhlir K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, et al. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). *Am J Kidney Dis* 2010;55(5):773-99. doi:10.1053/j.ajkd.2010.02.340
- Yokoyama K, Shimazaki R, Fukagawa M, Akizawa T. Long-term efficacy and safety of evocalcet in Japanese patients with secondary hyperparathyroidism receiving hemodialysis. *Sci Rep* 2019;9(1):6410. doi:10.1038/s41598-019-42017-z
- Boyer P, Ureña P, Brandenburg V, Goldsmith D, Ruiz C, DaSilva I, et al. Adynamic bone disease: from bone to vessels in chronic kidney disease. *Semin Nephrol* 2014;34(6):626-40. doi:10.1016/j.semnephrol.2014.09.008
- Sun IO, Chung BH, Yoon HJ, Kim JH, Choi BS, Park CW, et al. Clinical significance of red blood cell distribution width in the prediction of mortality in patients on peritoneal dialysis. *Kidney Res Clin Pract* 2016;35(2):114-8. doi:10.1016/j.krcp.2016.03.003
- Sista SK, Arum SM. Management of adynamic bone disease in chronic kidney disease: a brief review. *J Clin Transl Endocrinol* 2016;5:32-5. doi:10.1016/j.jcte.2016.07.002
- Magbri A, El-Magbri M, Hernandez PA. Get-up and go: adynamic bone disease in chronic kidney disease patient. *Arch Pharm Pract* 2023;14(1):11-5. doi:10.51847/suXosREK5t
- Gerevich J, Ungvari GS. The description of the litigious querulant: Heinrich von Kleist's Novella Michael Kohlhaas. *Psychopathology* 2015;48(2):79-83. doi:10.1159/000366562
- Hong YA, Kim JH, Kim YK, Chang YK, Park CW, Kim SY, et al. Low parathyroid hormone level predicts infection-related mortality in incident dialysis patients: a prospective cohort study. *Korean J Intern Med* 2020;35(1):160-70. doi:10.3904/kjim.2018.264
- Geethanjali R, Ganesh M, Jayaprakash V, Ramprasad E, Manikandan A, Rakchana M. Prevalence and biochemical profile of adynamic bone disease in a hemodialysis population. *Biomedicine* 2023;43(2):582-6. doi:10.51248/v43i02.1536
- Nagy E, Sobh MM, Abdalbary M, Elnagar S, Elrefaey R, Shabaka S, et al. Is adynamic bone always a disease? Lessons from patients with chronic kidney disease. *J Clin Med* 2022;11(23):7130. doi:10.3390/jcm11237130
- Belluoccio D, Etich J, Rosenbaum S, Frie C, Grskovic I, Stermann J, et al. Sorting of growth plate chondrocytes allows the isolation and characterization of cells of a defined differentiation status. *J Bone Miner Res* 2010;25(6):1267-81. doi:10.1002/jbmr.30
- Fehmi H, Osman Y, Bhat S, Nguyen K, Daramola O, Cantor T, et al. Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio. *Clin Nephrol* 2009;71(3):267-75. doi:10.5414/cnp.71267
- Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis* 2008;52(3):519-30. doi:10.1053/j.ajkd.2008.03.020
- Wagner M, Ansell D, Kent DM, Griffith JL, Naimark D, Wanner C, et al. Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. *Am J Kidney Dis* 2011;57(6):894-902. doi:10.1053/j.ajkd.2010.12.023
- Phelan PJ, O'Kelly P, Walshe JJ, Conlon PJ. The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients. *Ren Fail* 2008;30(4):423-9. doi:10.1080/08860220801964236

28. Wang SY, Zang XY, Fu SH, Bai J, Liu JD, Tian L, et al. Factors related to fatigue in Chinese patients with end-stage renal disease receiving maintenance hemodialysis: a multi-center cross-sectional study. *Ren Fail* 2016;38(3):442-50. doi:[10.3109/0886022x.2016.1138819](https://doi.org/10.3109/0886022x.2016.1138819)
29. Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. *Ther Apher Dial* 2013;17(3):247-88. doi:[10.1111/1744-9987.12058](https://doi.org/10.1111/1744-9987.12058)
30. Hsiung JT, Kleiner CE, Naderi N, Park C, Soohoo M, Moradi H, et al. Association of pre-end-stage renal disease serum albumin with post-end-stage renal disease outcomes among patients transitioning to dialysis. *J Ren Nutr* 2019;29(4):310-21. doi:[10.1053/j.jrn.2018.09.004](https://doi.org/10.1053/j.jrn.2018.09.004)
31. Yashiro M, Kamata T, Yamadori N, Tomita M, Muso E. Evaluation of markers to estimate volume status in hemodialysis patients: atrial natriuretic peptide, inferior vena cava diameter, blood volume changes and filtration coefficients of microvasculature. *Ther Apher Dial* 2007;11(2):131-7. doi:[10.1111/j.1744-9987.2007.00471.x](https://doi.org/10.1111/j.1744-9987.2007.00471.x)
32. Dukkipati R, Kovesdy CP, Colman S, Budoff MJ, Nissenson AR, Sprague SM, et al. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. *J Ren Nutr* 2010;20(4):243-54. doi:[10.1053/j.jrn.2009.10.006](https://doi.org/10.1053/j.jrn.2009.10.006)
33. Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. *Kidney Int* 2015;88(2):350-9. doi:[10.1038/ki.2015.72](https://doi.org/10.1038/ki.2015.72)
34. Ureña P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. *J Am Soc Nephrol* 1996;7(3):506-12. doi:[10.1681/asn.V73506](https://doi.org/10.1681/asn.V73506)
35. Blayney MJ, Pisoni RL, Bragg-Gresham JL, Bommer J, Piera L, Saito A, et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. *Kidney Int* 2008;74(5):655-63. doi:[10.1038/ki.2008.248](https://doi.org/10.1038/ki.2008.248)
36. Evenepoel P, Opdebeeck B, David K, D'Haese PC. Bone-vascular axis in chronic kidney disease. *Adv Chronic Kidney Dis* 2019;26(6):472-83. doi:[10.1053/j.ackd.2019.09.006](https://doi.org/10.1053/j.ackd.2019.09.006)
37. Siasos G, Tousoulis D, Michalea S, Oikonomou E, Kolia C, Kioufis S, et al. Biomarkers determining cardiovascular risk in patients with kidney disease. *Curr Med Chem* 2012;19(16):2555-71. doi:[10.2174/092986712800492986](https://doi.org/10.2174/092986712800492986)
38. Sit D, Kadiroglu AK, Kayabasi H, Atay AE, Yilmaz Z, Yilmaz ME. Relationship between bone mineral density and biochemical markers of bone turnover in hemodialysis patients. *Adv Ther* 2007;24(5):987-95. doi:[10.1007/bf02877703](https://doi.org/10.1007/bf02877703)
39. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. *Kidney Int* 1999;56(3):1084-93. doi:[10.1046/j.1523-1755.1999.00617.x](https://doi.org/10.1046/j.1523-1755.1999.00617.x)
40. Kanno Y, Kanda E, Kato A. Methods and nutritional interventions to improve the nutritional status of dialysis patients in JAPAN-a narrative review. *Nutrients* 2021;13(5):1390. doi:[10.3390/nu13051390](https://doi.org/10.3390/nu13051390)